SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Phage Therapeutics International Inc – ‘10SB12G/A’ on 12/5/01 – EX-10.9

On:  Wednesday, 12/5/01   ·   Accession #:  912057-1-542027   ·   File #:  0-31961

Previous ‘10SB12G’:  ‘10SB12G/A’ on 6/6/01   ·   Latest ‘10SB12G’:  This Filing

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of                Filer                Filing    For·On·As Docs:Size              Issuer               Agent

12/05/01  Phage Therapeutics Int’l Inc      10SB12G/A             24:1.4M                                   Merrill Corp/FA

Amendment to Registration of Securities of a Small-Business Issuer   —   Form 10-SB
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10SB12G/A   Amendment to Registration of Securities of a        HTML    725K 
                          Small-Business Issuer                                  
 2: EX-4.1      Instrument Defining the Rights of Security Holders  HTML     19K 
 3: EX-10.1     Material Contract                                   HTML     34K 
11: EX-10.10    Material Contract                                   HTML     79K 
12: EX-10.11    Material Contract                                   HTML     78K 
13: EX-10.12    Material Contract                                   HTML     53K 
14: EX-10.13    Material Contract                                   HTML     79K 
15: EX-10.14    Material Contract                                   HTML     22K 
16: EX-10.15    Material Contract                                   HTML     25K 
 4: EX-10.2     Material Contract                                   HTML     30K 
17: EX-10.22    Material Contract                                   HTML     38K 
18: EX-10.23    Material Contract                                   HTML     43K 
19: EX-10.24    Material Contract                                   HTML     43K 
20: EX-10.28    Material Contract                                   HTML     44K 
21: EX-10.29    Material Contract                                   HTML     64K 
 5: EX-10.3     Material Contract                                   HTML     42K 
22: EX-10.30    Material Contract                                   HTML     18K 
23: EX-10.33    Material Contract                                   HTML     46K 
 6: EX-10.4     Material Contract                                   HTML     80K 
 7: EX-10.5     Material Contract                                   HTML     22K 
 8: EX-10.6     Material Contract                                   HTML     18K 
 9: EX-10.8     Material Contract                                   HTML     19K 
10: EX-10.9     Material Contract                                   HTML     23K 
24: EX-21       Subsidiaries of the Registrant                      HTML      9K 


EX-10.9   —   Material Contract


This exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]



  Prepared by MERRILL CORPORATION  

Exhibit 10.9

SECURITIES PURCHASE AMENDING AGREEMENT

    THIS AGREEMENT dated as of the 1st day of March, 2001.

BETWEEN:

AND:

WHEREAS:

1


    NOW THEREFORE, for valuable consideration and upon the mutual covenants and promises contained herein, the parties hereto agree as follows:

First Paragraph

1.
This first paragraph of the Purchase Agreement shall read "AGREEMENT, dated as of October 23, 2000, between Phage Therapeutics International Inc. ("Phage") a Florida Corporation and the persons and entities listed on Schedule I ("Schedule of Purchasers for First Closing") and Schedule II ("Schedule of Purchasers Two for Second Closing") attached to this Agreement (collectively known as the "Purchaser" or "Purchasers").

Article 1: Definitions, Purchasers

2.
Article 1, Definitions, "Purchasers" be amended to state ""Purchasers" means the persons and entities listed on Schedule I "Schedule of Purchasers" for the First Closing and Schedule II "Schedule of Purchasers Two" for the Second Closing."

Article II. Purchase and Sale of Securities, 2.1(b)

3.
Article II, Purchase and Sale of Securities, section 2.1(b) be amended to state "at the Second Closing, Units in the amounts corresponding with the subscription amount set out opposite each Purchaser's name on Schedule II attached to this Agreement. The aggregate principal amount of all Units being issued at the Second Closing pursuant to this Agreement is One Million Five Hundred Thousand Dollars ($1,500,000).

Article VI. Affirmative Covenants, 6.15

4.
Article VI, Affirmative Covenants, section 6.15 be amended to state "Unit Offering. Subject to the satisfaction of the terms and conditions of this Agreement, the Purchasers irrevocably agree to invest an additional One Million Five Hundred Thousand Dollars ($1,500,000) in equity into Phage within seven (7) days from the date Phage files a Form 10SB-12g with the Commission. Phage in consideration of this investment has agreed to issue to the Purchasers 2,142,857 units on receipt of these funds. Each "Initial Unit" will consist of one share of Phage Common Stock and one common stock purchase warrant (the "Series One Warrant"). For every one and a half Warrants the holder will be entitled to acquire one additional share of common stock of Phage at an exercise price of $0.70 per share. These Warrants will be exercisable at any time on or before December 31, 2001 and their right of exercise will be subject to the Purchasers having fully exercised the Warrants received at the Initial Closing.

General

5.
All other terms of the Purchase Agreement will remain the same.

6.
The Purchase Agreement remains in full force and effect except as expressly amended by this Amending Agreement.

    IN WITNESS WHEREOF the parties hereto have caused this Agreement to be duly executed, all as of the day and year first above written.

PHAGE THERAPEUTICS INTERNATIONAL, INC.    

/s/ Darren Pylot


 

 

By:

 

Darren Pylot, President

 

 

2


PURCHASERS:

/s/ Robert Miller
  /s/ Unreadable
Name: Robert Miller   Name: Bolivar Longines SA

/s/ Ricardo Requena


 

/s/ Unreadable

Name: Ricardo Requena   Name: Cadaques S.A.

/s/ Blanca de Longo


 

/s/ Unreadable

Name: Blanca de Longo   Name: Stratton S.A.

/s/ Unreadable


 

/s/  

Name: GIG Limited   Alexandra Maz

3


SCHEDULE II

SCHEDULE OF PURCHASERS

Name
  Address/Facsimile Number
  $ Amount of Subscription
Robert Miller   1645 South Miami Avenue
Miami, FL 33129
  $ 211,000
Bolivar Longines SA   Centro Comercial Naraya
Piso 4 Oficina L-10
Alta Vista, Puerto Ordaz, Venezuela
  $ 280,000
Ricardo Requena   25 de Mayo 444 Piso 2
11000 Montevideo, Uruguay
  $ 539,000
Cadaques SA   Benito Blanco 675, Apt. 401
11300 Montevideo, Uruguay
  $ 125,000
Stratton SA   25 de Mayo 444, Piso 2
11000 Montevideo, Uruguay
  $ 275,000
Alexandra Maz   1645 South Miami Avenue
Miami, FL 33129
  $ 70,000

4




Dates Referenced Herein

This ‘10SB12G/A’ Filing    Date    Other Filings
12/31/01None on these Dates
Filed on:12/5/01
10/23/00
 List all Filings 
Top
Filing Submission 0000912057-01-542027   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Thu., Mar. 28, 5:41:44.1am ET